@article{ElHelouBiegnerBodeetal.2019,
  author    = {El-Helou, Sabine M. and Biegner, Anika-Kerstin and Bode, Sebastian and Ehl, Stephan R. and Heeg, Maximilian and Maccari, Maria E. and Ritterbusch, Henrike and Speckmann, Carsten and Rusch, Stephan and Scheible, Raphael and Warnatz, Klaus and Atschekzei, Faranaz and Beider, Renata and Ernst, Diana and Gerschmann, Stev and Jablonka, Alexandra and Mielke, Gudrun and Schmidt, Reinhold E. and Sch{\"u}rmann, Gesine and Sogkas, Georgios and Baumann, Ulrich H. and Klemann, Christian and Viemann, Dorothee and Bernuth, Horst von and Kr{\"u}ger, Renate and Hanitsch, Leif G. and Scheibenbogen, Carmen M. and Wittke, Kirsten and Albert, Michael H. and Eichinger, Anna and Hauck, Fabian and Klein, Christoph and Rack-Hoch, Anita and Sollinger, Franz M. and Avila, Anne and Borte, Michael and Borte, Stephan and Fasshauer, Maria and Hauenherm, Anja and Kellner, Nils and M{\"u}ller, Anna H. and {\"U}lzen, Anett and Bader, Peter and Bakhtiar, Shahrzad and Lee, Jae-Yun and Heß, Ursula and Schubert, Ralf and W{\"o}lke, Sandra and Zielen, Stefan and Ghosh, Sujal and Laws, Hans-Juergen and Neubert, Jennifer and Oommen, Prasad T. and H{\"o}nig, Manfred and Schulz, Ansgar and Steinmann, Sandra and Klaus, Schwarz and D{\"u}ckers, Gregor and Lamers, Beate and Langemeyer, Vanessa and Niehues, Tim and Shai, Sonu and Graf, Dagmar and M{\"u}glich, Carmen and Schmalzing, Marc T. and Schwaneck, Eva C. and Tony, Hans-Peter and Dirks, Johannes and Haase, Gabriele and Liese, Johannes G. and Morbach, Henner and Foell, Dirk and Hellige, Antje and Wittkowski, Helmut and Masjosthusmann, Katja and Mohr, Michael and Geberzahn, Linda and Hedrich, Christian M. and M{\"u}ller, Christiane and R{\"o}sen-Wolff, Angela and Roesler, Joachim and Zimmermann, Antje and Behrends, Uta and Rieber, Nikolaus and Schauer, Uwe and Handgretinger, Rupert and Holzer, Ursula and Henes, J{\"o}rg and Kanz, Lothar and Boesecke, Christoph and Rockstroh, J{\"u}rgen K. and Schwarze-Zander, Carolynne and Wasmuth, Jan-Christian and Dilloo, Dagmar and H{\"u}lsmann, Brigitte and Sch{\"o}nberger, Stefan and Schreiber, Stefan and Zeuner, Rainald and Ankermann, Tobias and Bismarck, Philipp von and Huppertz, Hans-Iko and Kaiser-Labusch, Petra and Greil, Johann and Jakoby, Donate and Kulozik, Andreas E. and Metzler, Markus and Naumann-Bartsch, Nora and Sobik, Bettina and Graf, Norbert and Heine, Sabine and Kobbe, Robin and Lehmberg, Kai and M{\"u}ller, Ingo and Herrmann, Friedrich and Horneff, Gerd and Klein, Ariane and Peitz, Joachim and Schmidt, Nadine and Bielack, Stefan and Groß-Wieltsch, Ute and Classen, Carl F. and Klasen, Jessica and Deutz, Peter and Kamitz, Dirk and Lassy, Lisa and Tenbrock, Klaus and Wagner, Norbert and Bernbeck, Benedikt and Brummel, Bastian and Lara-Villacanas, Eusebia and M{\"u}nstermann, Esther and Schneider, Dominik T. and Tietsch, Nadine and Westkemper, Marco and Weiß, Michael and Kramm, Christof and K{\"u}hnle, Ingrid and Kullmann, Silke and Girschick, Hermann and Specker, Christof and Vinnemeier-Laubenthal, Elisabeth and Haenicke, Henriette and Schulz, Claudia and Schweigerer, Lothar and M{\"u}ller, Thomas G. and Stiefel, Martina and Belohradsky, Bernd H. and Soetedjo, Veronika and Kindle, Gerhard and Grimbacher, Bodo},
  title     = {The German national registry of primary immunodeficiencies (2012-2017)},
  series = {Frontiers in Immunology},
  volume    = {10},
  journal   = {Frontiers in Immunology},
  doi       = {10.3389/fimmu.2019.01272},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-226629},
  year      = {2019},
  abstract  = {Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs. Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel. Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1-25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57\% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36\% of patients. Familial cases were observed in 21\% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0-88 years). Presenting symptoms comprised infections (74\%) and immune dysregulation (22\%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE-syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49\% of all patients received immunoglobulin G (IgG) substitution (70\%-subcutaneous; 29\%-intravenous; 1\%-unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy. Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.},
  language  = {en}
}
@phdthesis{Schmidt2002,
  author    = {Schmidt, Philipp},
  title     = {Vanadium(V)-katalysierte Oxidationen substituierter Bishomoallylalkohole zur stereoselektiven O-Heterocyclen-Synthese},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-3296},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2002},
  abstract  = {In der vorligenden Arbeit wurden Vanadium-abh{\"a}ngige Bromidperoxidase- (VBPO-) Modelle zur stereoselektiven Synthese funktionalisierter O-Heterocyclen entwickelt, die durch Vanadium-katalysierte Oxygenierung von Bishomoallylalkoholen mechanistisch untersucht wurden. Weiterhin wurden Bromcyclisierungen von Bishomoallylalkoholen auf enzymatischem (VBPO), oxidativem und radikalischem Weg f{\"u}r Referenzprodukte einer neuen Variante der Bromcyclisierung durch Vanadium-katalysierte Bromidoxidation durchgef{\"u}hrt. Die Selektivit{\"a}tsmuster aus den Synthesen ß-hydroxylierter und ß-bromierter Tetrahydrofurane wurden anschließend innerhalb einfacher Naturstoffsynthesen genutzt. Anhand eigener Vorarbeiten wurden neue Vanadium(V)-Komplexe aus Triethoxyvanadat mit tridentaten Schiffbaseliganden, basierend auf Salicylaldehyd und Aminoalkoholen mit strukturell unterschiedlichen Seitenketten in quantitativen Ausbeuten synthetisiert und charakterisiert (51V-NMR, UV und IR). In Test-Cyclisierungen unterschiedlicher Bishomoallylalkohole eignete sich VO(salin)(OEt) mit hohen Ums{\"a}tzen und guten Regio- wie Stereoselektivit{\"a}ten am besten. Die relative Geschwindigkeitskonstante (krel = 120±20) der Vanadium-katalysierten Oxidation des Testsystems konnte {\"u}ber Konkurrenzkinetik (Alkenol versus Alken) ermittelt werden und weist deutlich auf eine Bindung des Alkenols an Vanadium w{\"a}hrend der Oxidation hin. Um die Regio- und Stereoselektivit{\"a}ten Vanadium-Schiffbase-katalysierter Oxidationen von Bishomoallylalkoholen verstehen zu k{\"o}nnen, wurden stereochemische Studien anhand des Testsystems durchgef{\"u}hrt. Dessen Oxidation wird demnach im selektivit{\"a}tsbestimmenden Schritt dem Metallzentrum abgewandt in like-Position bevorzugt gebildet und f{\"u}hrt zu dem cis-konfigurierten Tetrahydrofuran als Hauptprodukt. Im Folgenden wurden Vanadium-katalysierte Oxidationen unterschiedlich substituierter bishomoallylischer Alkohole durchgef{\"u}hrt, s{\"a}mtliche Oxidationen f{\"u}hrten regioselektiv zu Tetrahydrofuranen als Hauptprodukte, die Oxygenierung Dimethyl-substituierter Pentenole lieferte durch Substitution an C-1 selektiv cis-konfigurierte Tetrahydrofurane, 2-Substitution f{\"u}hrte ebenso wie 3-Substitution zu trans-konfigurierte Oxolanen. Alkohole nicht aktivierter Olefine wurden in der Reihenfolge C-1 ? C-3 mit h{\"o}herer Selektivit{\"a}t zu trans-konfigurierten Tetrahydrofuranen gebildet. Die Regio- und Stereoselektivit{\"a}ten der radikalischen Bromcyclisierungen folgen den schon in fr{\"u}heren Arbeiten unserer Arbeitsgruppe aufgestellten Richtlinien (5-exo-trig; 2,5-trans, 2,4-cis und 2,3-trans). Die ionischen Bromcyclisierungen 5,5-dimethylierter Bishomoallyl-alkohole mittels NBS verliefen komplement{\"a}r zu den Radikal-Cyclisierungen regioselektiv und in Abh{\"a}ngigkeit der Phenylsubstituenten an C-1 - C-3 stereoselektiv zu den 2,5-trans-, 3,5-cis- und 4,5-trans-konfigurierten Tetrahydropyranen. Aus der Bromcyclisierung prochiraler Pentenole in Gegenwart eines Acetonpulvers aus Ascophyllum nodosum (A.n.A.P.) konnte das b-bromierte Tetrahydrofuran racemisch in 87proz. Ausbeute erhalten werden. Ebensowenig f{\"u}hrte der Einsatz chiraler Liganden in der Vanadium-katalysierten Oxygenierung prochiraler Penten-1-ole bei guten Ausbeuten (>80\%) zu Enantiomeren-angereicherten Tatrahydrofuranen. Innerhalb einfacher Naturstoffsynthesen wurden cis-Pityol, Linalooloxid sowie (-)-epi-Bisabololoxid selektiv unter Standardbedingungen der Vanadium-Schiffbase-katalysierten Oxidationen mit VO(salin)(OEt) und TBHP dargestellt. Die Stereoselektivit{\"a}ten steigen proportional zu dem Gr{\"o}ßenunterschied der Substituenten an Position 1 der Bishomoallylalkohole. Abschließend wurde durch Vanadium-katalysierte Bromidoxiadtion mit TBHP eine neue dreistufige Totalsynthese der vier "nat{\"u}rlichen" Muscarin-Isomere ausgearbeitet. Die Gesamtausbeuten dieser Synthesen liegen zwischen 3.0 und 19.9\%.},
  subject      = {Vanadium},
  language  = {de}
}
@article{SchmidtAltDeoghareetal.2022,
  author    = {Schmidt, Sven and Alt, Yvonne and Deoghare, Nikita and Kr{\"u}ger, Sarah and Kern, Anna and Rockel, Anna Frederike and Wagner, Nicole and Erg{\"u}n, S{\"u}leyman and W{\"o}rsd{\"o}rfer, Philipp},
  title     = {A blood vessel organoid model recapitulating aspects of vasculogenesis, angiogenesis and vessel wall maturation},
  series = {Organoids},
  volume    = {1},
  journal   = {Organoids},
  number    = {1},
  issn      = {2674-1172},
  doi       = {10.3390/organoids1010005},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-284043},
  pages     = {41 -- 53},
  year      = {2022},
  abstract  = {Blood vessel organoids are an important in vitro model to understand the underlying mechanisms of human blood vessel development and for toxicity testing or high throughput drug screening. Here we present a novel, cost-effective, and easy to manufacture vascular organoid model. To engineer the organoids, a defined number of human induced pluripotent stem cells are seeded in non-adhesive agarose coated wells of a 96-well plate and directed towards a lateral plate mesoderm fate by activation of Wnt and BMP4 signaling. We observe the formation of a circular layer of angioblasts around days 5-6. Induced by VEGF application, CD31\(^+\) vascular endothelial cells appear within this vasculogenic zone at approximately day 7 of organoid culture. These cells arrange to form a primitive vascular plexus from which angiogenic sprouting is observed after 10 days of culture. The differentiation outcome is highly reproducible, and the size of organoids is scalable depending on the number of starting cells. We observe that the initial vascular ring forms at the interface between two cell populations. The inner cellular compartment can be distinguished from the outer by the expression of GATA6, a marker of lateral plate mesoderm. Finally, 14-days-old organoids were transplanted on the chorioallantois membrane of chicken embryos resulting in a functional connection of the human vascular network to the chicken circulation. Perfusion of the vessels leads to vessel wall maturation and remodeling as indicated by the formation of a continuous layer of smooth muscle actin expressing cells enwrapping the endothelium. In summary, our organoid model recapitulates human vasculogenesis, angiogenesis as well as vessel wall maturation and therefore represents an easy and cost-effective tool to study all steps of blood vessel development and maturation directly in the human setting without animal experimentation.},
  language  = {en}
}
@article{HerrmannLotzKaragiannidisetal.2022,
  author    = {Herrmann, Johannes and Lotz, Christopher and Karagiannidis, Christian and Weber-Carstens, Steffen and Kluge, Stefan and Putensen, Christian and Wehrfritz, Andreas and Schmidt, Karsten and Ellerkmann, Richard K. and Oswald, Daniel and Lotz, G{\"o}sta and Zotzmann, Viviane and Moerer, Onnen and K{\"u}hn, Christian and Kochanek, Matthias and Muellenbach, Ralf and Gaertner, Matthias and Fichtner, Falk and Brettner, Florian and Findeisen, Michael and Heim, Markus and Lahmer, Tobias and Rosenow, Felix and Haake, Nils and Lepper, Philipp M. and Rosenberger, Peter and Braune, Stephan and Kohls, Mirjam and Heuschmann, Peter and Meybohm, Patrick},
  title     = {Key characteristics impacting survival of COVID-19 extracorporeal membrane oxygenation},
  series = {Critical Care},
  volume    = {26},
  journal   = {Critical Care},
  number    = {1},
  doi       = {10.1186/s13054-022-04053-6},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-299686},
  year      = {2022},
  abstract  = {Background Severe COVID-19 induced acute respiratory distress syndrome (ARDS) often requires extracorporeal membrane oxygenation (ECMO). Recent German health insurance data revealed low ICU survival rates. Patient characteristics and experience of the ECMO center may determine intensive care unit (ICU) survival. The current study aimed to identify factors affecting ICU survival of COVID-19 ECMO patients. Methods 673 COVID-19 ARDS ECMO patients treated in 26 centers between January 1st 2020 and March 22nd 2021 were included. Data on clinical characteristics, adjunct therapies, complications, and outcome were documented. Block wise logistic regression analysis was applied to identify variables associated with ICU-survival. Results Most patients were between 50 and 70 years of age. PaO\(_{2}\)/FiO\(_{2}\) ratio prior to ECMO was 72 mmHg (IQR: 58-99). ICU survival was 31.4\%. Survival was significantly lower during the 2nd wave of the COVID-19 pandemic. A subgroup of 284 (42\%) patients fulfilling modified EOLIA criteria had a higher survival (38\%) (p = 0.0014, OR 0.64 (CI 0.41-0.99)). Survival differed between low, intermediate, and high-volume centers with 20\%, 30\%, and 38\%, respectively (p = 0.0024). Treatment in high volume centers resulted in an odds ratio of 0.55 (CI 0.28-1.02) compared to low volume centers. Additional factors associated with survival were younger age, shorter time between intubation and ECMO initiation, BMI > 35 (compared to < 25), absence of renal replacement therapy or major bleeding/thromboembolic events. Conclusions Structural and patient-related factors, including age, comorbidities and ECMO case volume, determined the survival of COVID-19 ECMO. These factors combined with a more liberal ECMO indication during the 2nd wave may explain the reasonably overall low survival rate. Careful selection of patients and treatment in high volume ECMO centers was associated with higher odds of ICU survival.},
  language  = {en}
}
@article{DoganScheuringWagneretal.2021,
  author    = {Dogan, Leyla and Scheuring, Ruben and Wagner, Nicole and Ueda, Yuichiro and Schmidt, Sven and W{\"o}rsd{\"o}rfer, Philipp and Groll, J{\"u}rgen and Erg{\"u}n, S{\"u}leyman},
  title     = {Human iPSC-derived mesodermal progenitor cells preserve their vasculogenesis potential after extrusion and form hierarchically organized blood vessels},
  series = {Biofabrication},
  volume    = {13},
  journal   = {Biofabrication},
  number    = {4},
  doi       = {10.1088/1758-5090/ac26ac},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-254046},
  year      = {2021},
  abstract  = {Post-fabrication formation of a proper vasculature remains an unresolved challenge in bioprinting. Established strategies focus on the supply of the fabricated structure with nutrients and oxygen and either rely on the mere formation of a channel system using fugitive inks or additionally use mature endothelial cells and/or peri-endothelial cells such as smooth muscle cells for the formation of blood vessels in vitro. Functional vessels, however, exhibit a hierarchical organization and multilayered wall structure that is important for their function. Human induced pluripotent stem cell-derived mesodermal progenitor cells (hiMPCs) have been shown to possess the capacity to form blood vessels in vitro, but have so far not been assessed for their applicability in bioprinting processes. Here, we demonstrate that hiMPCs, after formulation into an alginate/collagen type I bioink and subsequent extrusion, retain their ability to give rise to the formation of complex vessels that display a hierarchical network in a process that mimics the embryonic steps of vessel formation during vasculogenesis. Histological evaluations at different time points of extrusion revealed the initial formation of spheres, followed by lumen formation and further structural maturation as evidenced by building a multilayered vessel wall and a vascular network. These findings are supported by immunostainings for endothelial and peri-endothelial cell markers as well as electron microscopic analyses at the ultrastructural level. Moreover, endothelial cells in capillary-like vessel structures deposited a basement membrane-like matrix at the basal side between the vessel wall and the alginate-collagen matrix. After transplantation of the printed constructs into the chicken chorioallantoic membrane (CAM) the printed vessels connected to the CAM blood vessels and get perfused in vivo. These results evidence the applicability and great potential of hiMPCs for the bioprinting of vascular structures mimicking the basic morphogenetic steps of de novo vessel formation during embryogenesis.},
  language  = {en}
}
@article{JanjetovicLohneisNogaietal.2021,
  author    = {Janjetovic, Snjezana and Lohneis, Philipp and Nogai, Axel and Balci, Derya and Rasche, Leo and J{\"a}hne, Doris and Bokemeyer, Carsten and Schilling, Georgia and Blau, Igor Wolfgang and Schmidt-Hieber, Martin},
  title     = {Clinical and biological characteristics of medullary and extramedullary plasma cell dyscrasias},
  series = {Biology},
  volume    = {10},
  journal   = {Biology},
  number    = {7},
  issn      = {2079-7737},
  doi       = {10.3390/biology10070629},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-242592},
  year      = {2021},
  abstract  = {Background: Extramedullary plasma cell (PC) disorders may occur as extramedullary disease in multiple myeloma (MM-EMD) or as primary extramedullary plasmocytoma (pEMP)/solitary osseous plasmocytoma (SOP). In this study, we aimed to obtain insights into the molecular mechanisms of extramedullary spread of clonal PC. Methods: Clinical and biological characteristics of 87 patients with MM-EMD (n = 49), pEMP/SOP (n = 20) and classical MM (n = 18) were analyzed by using immunohistochemistry (CXCR4, CD31, CD44 and CD81 staining) and cytoplasmic immunoglobulin staining combined with fluorescence in situ hybridization (cIg-FISH). Results: High expression of CD44, a cell-surface glycoprotein involved in cell-cell interactions, was significantly enriched in MM-EMD (90\%) vs. pEMP/SOP (27\%) or classical MM (33\%) (p < 0.001). In addition, 1q21 amplification by clonal PC occurred at a similar frequency of MM-EMD (33\%), pEMP/SOP (57\%) and classical MM (44\%). Conversely, del(17p13), t(4;14) and t(14;16) were completely absent in pEMP/SOP. Besides this, 1q21 amplification was identified in 64\% of not paraskeletal samples from MM-EMD or pEMP compared to 9\% of SOP or paraskeletal MM-EMD/pEMP and 44\% of classical MM samples, respectively (p = 0.02). Conclusion: Expression of molecules involved in homing and cytogenetic aberrations differ between MM with or without EMD and pEMP/SOP.},
  language  = {en}
}
@article{JakuscheitSchaeferRoedigetal.2021,
  author    = {Jakuscheit, Axel and Schaefer, Nina and Roedig, Johannes and Luedemann, Martin and Hertzberg-Boelch, Sebastian Philipp von and Weissenberger, Manuel and Schmidt, Karsten and Holzapfel, Boris Michael and Rudert, Maximilian},
  title     = {Modifiable individual risks of perioperative blood transfusions and acute postoperative complications in total hip and knee arthroplasty},
  series = {Journal of Personalized Medicine},
  volume    = {11},
  journal   = {Journal of Personalized Medicine},
  number    = {11},
  issn      = {2075-4426},
  doi       = {10.3390/jpm11111223},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-250290},
  year      = {2021},
  abstract  = {Background: The primary aim of this study was to identify modifiable patient-related predictors of blood transfusions and perioperative complications in total hip and knee arthroplasty. Individual predictor-adjusted risks can be used to define preoperative treatment thresholds. Methods: We performed this retrospective monocentric study in orthopaedic patients who underwent primary total knee or hip arthroplasty. Multivariate logistic regression models were used to assess the predictive value of patient-related characteristics. Predictor-adjusted individual risks of blood transfusions and the occurrence of any perioperative adverse event were calculated for potentially modifiable risk factors. Results: 3754 patients were included in this study. The overall blood transfusion and complication rates were 4.8\% and 6.4\%, respectively. Haemoglobin concentration (Hb, p < 0.001), low body mass index (BMI, p < 0.001) and estimated glomerular filtration rate (eGFR, p = 0.004) were the strongest potentially modifiable predictors of a blood transfusion. EGFR (p = 0.001) was the strongest potentially modifiable predictor of a complication. Predictor-adjusted risks of blood transfusions and acute postoperative complications were calculated for Hb and eGFR. Hb = 12.5 g/dL, BMI = 17.6 kg/m\(^2\), and eGFR = 54 min/mL were associated, respectively, with a 10\% risk of a blood transfusion, eGFR = 59 mL/min was associated with a 10\% risk of a complication. Conclusion: The individual risks for blood transfusions and acute postoperative complications are strongly increased in patients with a low preoperative Hb, low BMI or low eGFR. We recommend aiming at a preoperative Hb ≥ 13g/dL, an eGFR ≥ 60 mL/min and to avoid a low BMI. Future studies must show if a preoperative increase of eGFR and BMI is feasible and truly beneficial.},
  language  = {en}
}
@article{SummaKleinSchmidt2022,
  author    = {Summa, Michela and Klein, Martin and Schmidt, Philipp},
  title     = {Introduction: Double Intentionality},
  series = {Topoi},
  volume    = {41},
  journal   = {Topoi},
  number    = {1},
  issn      = {1572-8749},
  doi       = {10.1007/s11245-021-09786-7},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-269865},
  pages     = {93-109},
  year      = {2022},
  abstract  = {No abstract available.},
  language  = {en}
}